Igc Pharma earnings were -$5.3M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest IGC earnings report on Dec 31, 2025 announced Q4 2025 earnings of -$726.0k, down 60.1% from last quarter. For the last reported fiscal year 2025 ending Mar 31, 2025, IGC reported annual earnings of -$7.1M, with -45.2% growth.
On IGC's earnings call on Invalid Date, Igc Pharma (NYSEMKT: IGC) reported Q4 2025 earnings per share (EPS) of -$0.01, up 50% year over year. Total IGC earnings for the quarter were -$726.00 thousand. In the same quarter last year, Igc Pharma's earnings per share (EPS) was -$0.02.
As of the last Igc Pharma earnings report, Igc Pharma is currently losing money. Igc Pharma's net profit (also called net income) for the twelve months ending Dec 31, 2025 was -$5.34 million, a 39.35% decrease year over year.
What was IGC's earnings growth in the past year?
As of Igc Pharma's earnings date in Invalid Date, Igc Pharma's earnings has grown year over year. IGC earnings in the past year totalled -$5.34 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.